Epigenetic Silencing of CXCL14 Induced Colorectal Cancer Migration and Invasion

Overview

Journal Discov Med

Specialty General Medicine

Date 2013 Oct 9

PMID 24099668

Citations 31

Authors

Baoping Cao

Yunsheng Yang

Yuanming Pan

Yan Jia

Malcolm V Brock

James G Herman

Mingzhou Guo

Affiliations

Soon will be listed here.

Abstract

To explore epigenetic regulation and the impact of chemokine CXCL14 on colorectal cancer, 7 colorectal cancer cell lines, 107 cases of primary colorectal cancer, and 10 cases of normal colorectal mucosa were evaluated in this study. Methylation specific PCR (MSP), semi-quantitative reverse-transcription PCR (RT-PCR), cell proliferation assay, colony formation, and transwell assay were performed for the evaluation. Complete methylation and loss of CXCL14 expression were found in 5 colorectal cancer cell lines. Partial methylation and weak expression were found in two cell lines. CXCL14 was methylated in 79.4% (85/107) of primary human colorectal cancer. No methylation was found in 10 cases of normal colorectal mucosa. Restoration of CXCL14 expression was induced by the 5-aza-2'-deoxycytidine (DAC) treatment. The cell viability was reduced and colony formation was inhibited by restoration of CXCL14 expression in HCT116 cells, a colorectal cancer cell line. The number of invasive and migration cells was reduced by CXCL14. The expression of MMP-2, Vimentin, and NF-κB was suppressed, and the expression of E-cadherin and IκB-α was induced by CXCL14. In conclusion, CXCL14 is frequently methylated in human colorectal cancer and promoter region hypermethylation silenced CXCL14 expression in colorectal cancer cells. Restoration of CXCL14 expression suppressed colorectal cancer proliferation. CXCL14 inhibits colorectal cancer migration, invasion, and epithelial-to-mesenchymal transition (EMT) by suppressing NF-κB signaling.

Citing Articles

The Chemokine CXCL14 as a Potential Immunotherapeutic Agent for Cancer Therapy.

Giacobbi N, Mullapudi S, Nabors H, Pyeon D Viruses. 2024; 16(2).

PMID: 38400076 PMC: 10892169. DOI: 10.3390/v16020302.

Data Mining Suggests That CXCL14 Gene Silencing in Colon Cancer Is Due to Promoter Methylation.

Wang Y, Wang S, Niu Y, Ma B, Li J Int J Mol Sci. 2023; 24(22).

PMID: 38003215 PMC: 10671198. DOI: 10.3390/ijms242216027.

CXCL5 and CXCL14, but not CXCL16 as potential biomarkers of colorectal cancer.

Zajkowska M, Dulewicz M, Kulczynska-Przybik A, Safiejko K, Juchimiuk M, Konopko M Sci Rep. 2023; 13(1):17688.

PMID: 37848726 PMC: 10582048. DOI: 10.1038/s41598-023-45093-4.

A Novel Approach to Staging and Detection of Colorectal Cancer in Early Stages.

Zajkowska M, Mroczko B J Clin Med. 2023; 12(10).

PMID: 37240636 PMC: 10218832. DOI: 10.3390/jcm12103530.

Emerging Role of Plant-Based Dietary Components in Post-Translational Modifications Associated with Colorectal Cancer.

Rodriguez-Garcia C, Gutierrez-Santiago F Life (Basel). 2023; 13(2).

PMID: 36836621 PMC: 9962725. DOI: 10.3390/life13020264.

References

Huber M, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H . NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest. 2004; 114(4):569-81. PMC: 503772. DOI: 10.1172/JCI21358. View

Chen W, Zhang S, Zou X, Zhao P . Cancer incidence and mortality in china, 2006. Chin J Cancer Res. 2013; 23(1):3-9. PMC: 3587531. DOI: 10.1007/s11670-011-0003-9. View

Jia Y, Guo M . Epigenetic changes in colorectal cancer. Chin J Cancer. 2011; 32(1):21-30. PMC: 3845587. DOI: 10.5732/cjc.011.10245. View

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

Nozawa H, Oda E, Ueda S, Tamura G, Maesawa C, Muto T . Functionally inactivating point mutation in the tumor-suppressor IRF-1 gene identified in human gastric cancer. Int J Cancer. 1998; 77(4):522-7. DOI: 10.1002/(sici)1097-0215(19980812)77:4<522::aid-ijc8>3.0.co;2-w. View

Miyazaki H, Takabe K, Yeudall W . Chemokines, chemokine receptors and the gastrointestinal system. World J Gastroenterol. 2013; 19(19):2847-63. PMC: 3660811. DOI: 10.3748/wjg.v19.i19.2847. View

Zeng J, Yang X, Cheng L, Liu R, Lei Y, Dong D . Chemokine CXCL14 is associated with prognosis in patients with colorectal carcinoma after curative resection. J Transl Med. 2013; 11:6. PMC: 3551837. DOI: 10.1186/1479-5876-11-6. View

Shurin G, Ferris R, Ferris R, Tourkova I, Perez L, Lokshin A . Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J Immunol. 2005; 174(9):5490-8. DOI: 10.4049/jimmunol.174.9.5490. View

Beder L, Gunduz M, Ouchida M, Fukushima K, Gunduz E, Ito S . Genome-wide analyses on loss of heterozygosity in head and neck squamous cell carcinomas. Lab Invest. 2003; 83(1):99-105. DOI: 10.1097/01.lab.0000047489.26246.e1. View

10.

Park C, You D, Kim D, Moon M, Lee C, Oh S . CXCL14 enhances proliferation and migration of NCI-H460 human lung cancer cells overexpressing the glycoproteins containing heparan sulfate or sialic acid. J Cell Biochem. 2012; 114(5):1084-96. DOI: 10.1002/jcb.24449. View

11.

Licchesi J, Herman J . Methylation-specific PCR. Methods Mol Biol. 2008; 507:305-23. DOI: 10.1007/978-1-59745-522-0_22. View

12.

Edwards B, Ward E, Kohler B, Eheman C, Zauber A, Anderson R . Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2009; 116(3):544-73. PMC: 3619726. DOI: 10.1002/cncr.24760. View

13.

Zhang W, Glockner S, Guo M, Machida E, Wang D, Easwaran H . Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res. 2008; 68(8):2764-72. PMC: 2823123. DOI: 10.1158/0008-5472.CAN-07-6349. View

14.

Starnes T, Rasila K, Robertson M, Brahmi Z, Dahl R, Christopherson K . The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy. Exp Hematol. 2006; 34(8):1101-5. DOI: 10.1016/j.exphem.2006.05.015. View

15.

Center M, Jemal A, Smith R, Ward E . Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009; 59(6):366-78. DOI: 10.3322/caac.20038. View

16.

Wente M, Mayer C, Gaida M, Michalski C, Giese T, Bergmann F . CXCL14 expression and potential function in pancreatic cancer. Cancer Lett. 2007; 259(2):209-17. DOI: 10.1016/j.canlet.2007.10.021. View

17.

Gu X, Ou Z, Lin F, Yang X, Luo J, Shen Z . Expression of CXCL14 and its anticancer role in breast cancer. Breast Cancer Res Treat. 2012; 135(3):725-35. DOI: 10.1007/s10549-012-2206-2. View

18.

Shellenberger T, Wang M, Gujrati M, Jayakumar A, Strieter R, Burdick M . BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res. 2004; 64(22):8262-70. DOI: 10.1158/0008-5472.CAN-04-2056. View

19.

Riojas M, Guo M, Glockner S, Machida E, Baylin S, Ahuja N . Methylation-induced silencing of ASC/TMS1, a pro-apoptotic gene, is a late-stage event in colorectal cancer. Cancer Biol Ther. 2007; 6(11):1710-6. DOI: 10.4161/cbt.6.11.4829. View

20.

Yin D, Jia Y, Yu Y, Brock M, Herman J, Han C . SOX17 methylation inhibits its antagonism of Wnt signaling pathway in lung cancer. Discov Med. 2012; 14(74):33-40. PMC: 4061568. View